Emilie Sohier

145P Identification of biomarkers of survival across multiple cancer types using eXplainable artificial intelligence

Filippo Flavio Angileri, Manuel Kindermans, Valéry Attignon, Mohammad Afshar et autres

fr (code pays fourni par la source)

Different Genetic Signatures of Small‐Cell Lung Cancer Characterize Anti‐GABA B R and Anti‐Hu Paraneoplastic Neurological Syndromes

Alberto Vogrig, Antoine Pégat, Macarena Villagrán‐García, Valentin Wucher et autres

Objective Small‐cell lung cancer (SCLC) is the malignancy most frequently associated with paraneoplastic neurological syndromes (PNS) and can trigger different antibody responses against intracellular (Hu) or neuronal surface (GABA B R) antigens. Our aim was to clarify whether the genomic and transcriptomic …

fr, it, us (code pays fourni par la source)

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montané et autres

Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on patients with tumors harboring sorafenib-targeted genes. Methods: The MOST-plus trial used a …

fr (code pays fourni par la source)

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montané et autres

Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on patients with tumors harboring sorafenib-targeted genes Methods: The MOST-plus trial used a …

fr, in (code pays fourni par la source)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial

Elise Bonnet, Véronique Haddad, Stanislas Quesada, Kim-Arthur Baffert et autres

Background: a specific subset of metastatic triple-negative breast cancers (mTNBC) is characterized by homologous recombination deficiency (HRD), leading to enhanced sensitivity to platinum-based chemotherapy. Apart from mutations in BRCA1/2 genes, the evaluation of other HRD-related alterations has been limited to date. As …

fr (code pays fourni par la source)

Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial

Jean-David Fumet, Émilie Lardenois, Isabelle Ray‐Coquard, Philipp Harter et autres

Background: Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment (TME) according to genomic instability in high grade serous ovarian carcinoma (HGSOC) …

fr, de (code pays fourni par la source)

Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial

Alice Bonneville-Levard, Didier Frappaz, Olivier Trédan, Emilie Lavergne et autres

fr (code pays fourni par la source)

Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub‐analysis of the ProfiLER protocol

Elise Rowinski, Nicolas Magné, Jérôme Fayette, Élisabeth Daguenet et autres

BACKGROUND: Genome analysis could provide tools to assess predictive molecular biomarkers of radioresistance. METHODS: Head and neck squamous cell carcinoma patients included in ProfiLER study and who underwent a curative radiotherapy were screened. Univariate and Cox multivariate analyses were performed to explore …

fr (code pays fourni par la source)

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

Owen Hoare, Nicolás A. Fraunhoffer, Abdessamad El-Kaoutari, Odile Gayet et autres

Purpose: Compare pancreatic ductal adenocarcinoma (PDAC), preclinical models, by their transcriptome and drug response landscapes to evaluate their complementarity. Experimental Design: Three paired PDAC preclinical models—patient-derived xenografts (PDX), xenograft-derived pancreatic organoids (XDPO) and xenograft-derived primary cell cultures (XDPCC)—were derived from 20 patients …

fr (code pays fourni par la source)

Acquired somatic MMR deficiency is a major cause of MSI tumor in patients suspected for “Lynch-like syndrome” including young patients

Cédrick Lefol, Emilie Sohier, Christian Baudet, Pierre Naïbo et autres

fr (code pays fourni par la source)

Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial

Patrick Arnaud‐Coffin, Mehdi Brahmi, Hélène Vanacker, Lauriane Eberst et autres

BACKGROUND: Advanced sarcoma is a group of heterogeneous disease with poor prognosis and poor efficacy of medical treatment. They represent a promising group of tumors to assess molecular-based therapy (MBT) strategy. PATIENTS AND METHODS: Genomic profiles of patients with advanced sarcoma included …

fr (code pays fourni par la source)

Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme

Romain Varnier, Olivia Le Saux, Sylvie Chabaud, Gwenaëlle Garin et autres

OBJECTIVES: The objectives of this study were to identify actionable genomic alterations in the gynaecological subpopulation of the ProfiLER programme and to report clinical efficacy of recommended targeted treatment (RTT). METHODS: The ProfiLER programme (NCT01774409) is a multicentric prospective trial aiming to …

fr (code pays fourni par la source)